BASF Settles With US FTC About False Fatty Liver Claims For Hepaxa Omega-3 Supplements
German multi-national and a former US distributor agreed to pay more than $416,000 to US FTD for unsupported claims about omega-3 supplements for adults and children. In complaint, FTC alleged the firms “cherry picked” data from supporting human studies to fit claims.
You may also be interested in...
Kyowa Hakko unveils supplement ingredient Eyemuse, a heat-treated “parabiotic” found to reduce eye fatigue, filter blue light and support a balanced immune response. CRN campaign educates retailers, consumers about probiotics and helps retailers improve handling of the products.
Wellness products accounted for the highest number of launches among health, wellness and beauty products at independent pharmacies in 2020. But the overall number slumped 21.1% due to the pandemic, according to Hamacher Resource Group’s report on a product rating system.
FDA is conducting lab testing on CBD products with funding in its FY2021 appropriations, says senior agency advisor Sharon Mayl. Some work planned work in the area has been delayed by the agency's response to COVID-19.